Obesity White Papers & Case Studies

  1. Relieving Pressure During Preparation Of A High-Volume sNDA 5/27/2026

    Managing a complex sNDA under pressure? See how one sponsor achieved an early FDA submission through coordinated publishing, regulatory strategy, and flawless execution.

  2. Supporting Global Approval Of A First-In-Class Gene Therapy For A Rare Genetic Disorder 5/27/2026

    Global approvals for a first-in-class gene therapy don’t happen by chance. See how adaptive oversight and inspection readiness kept a complex rare disease program moving forward.

  3. How Expert Medical Information Support Strengthened A Rare Respiratory Therapy Launch 5/26/2026

    Embedded medical information expertise enabled compliant, real‑time scientific engagement with healthcare professionals at a high‑profile congress during a critical product launch.

  4. Urgent Compliance Recovery Following Vendor Transition 5/26/2026

    Rapid local leadership, clear ownership of corrective actions, and governed oversight enabled time‑critical remediation of legacy safety gaps, restoring regulatory confidence and protecting market continuity under intense inspection pressure.

  5. Inspection Facilitation Without Local MAH Presence 5/26/2026

    Local expertise and centralized oversight ensured compliant, well‑coordinated inspections across countries, reducing operational risk and client burden while maintaining consistent authority engagement.

  6. Continuity And Risk Mitigation Following Unexpected QPPV Resignation 5/26/2026

    Rapid escalation and clear interim governance ensured compliance and operational continuity following an unexpected QPPV resignation, reducing inspection risk during a critical pharmacovigilance transition.

  7. Transforming European Case Intake Operations 5/26/2026

    Centralized intake and semi‑automation brought clarity and control to European safety reporting, improving oversight, data quality, and compliance across multiple partners and countries.

  8. Faster Starts, Stronger Finish: Operational Excellence In NSCLC 5/22/2026

    In NSCLC trials, data‑driven site selection, streamlined protocols, efficient screening strategies, and proactive engagement can accelerate enrollment and improve trial efficiency across regions.

  9. How Adaptive Design Accelerates Early‑Phase NSCLC Development 5/22/2026

    Adaptive trial designs and an adaptive mindset enable non-small cell lung cancer (NSCLC) sponsors to optimize dose, respond to evolving expectations, and accelerate early‑phase development.

  10. Data-Driven Paths To Rare/Ultra-Rare Disease Therapy Approval 5/22/2026

    Explore how integrated regulatory, statistical, and operational expertise can be applied to help sponsors navigate complex development pathways and accelerate global approvals.